Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie av LY4515100 på friska deltagare

17 november 2026 uppdaterad av: Eli Lilly and Company

En fas 1-studie, randomiserad, blindad för utredare och deltagare, placebokontrollerad, med enkel- och multipelstegsdosering för att karakterisera säkerhet, tolerabilitet och farmakokinetik för LY4515100 hos friska deltagare

The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. LY4515100 will be given by itself or with other medicines. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will have 3 parts and will last about 50 days. For each participant in Part A, the study will include a stay in the Clinical Research Unit (CRU) lasting about 6 days. For each participant in Part B, the study will include a stay in the CRU lasting about 15 days. For each participant in Part C, the study will include up to 2 stays in the CRU each lasting between 7-28 days.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

209

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
  • Telefonnummer: 1-317-615-4559
  • E-post: LillyTrials@Lilly.com

Studera Kontakt Backup

Studieorter

    • Texas
      • Dallas, Texas, Förenta staterna, 75247
        • Rekrytering
        • Fortrea Clinical Research Unit
        • Huvudutredare:
          • Gene Voskuhl
        • Kontakt:
          • Telefonnummer: 866-429-3700
    • Wisconsin
      • Madison, Wisconsin, Förenta staterna, 53704
        • Rekrytering
        • Fortrea Clinical Research Unit
        • Huvudutredare:
          • Kimberly Cruz
        • Kontakt:
          • Telefonnummer: 866-429-3700

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 65 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring.

  • Have a body mass index (BMI) within the range of 18.5 to 32.0 kilograms per square meter (kg/m²) (inclusive).

  • Individuals not of childbearing potential (INOCBP) may participate in this trial.

  • Participants in the Combined Oral Contraceptive Arm of Part C only:

    • must be 18 to 45 years of age (inclusive).
    • have a BMI within the range of 18.5 to 30 kg/m².
    • may be healthy pre-menopausal assigned female at birth (AFAB) individuals of child bearing potential (IOCBP).

Exclusion Criteria:

  • Have donated 500 milliliters (mL) of blood within 30 days prior to dosing.

  • Have participated within the last 30 days in a clinical study involving an investigational medicinal product. If the previous investigational product (IP) has a long half-life, 5 half-lives or 30 days (whichever is longer) should have passed.

  • Participants with hemoglobin outside of the local laboratory normal reference range for age and sex, which is judged to be clinically significant by the investigator.

  • Participants with an estimated glomerular filtration rate less than (<) 90 milliliter per minute per 1.73 square meters (mL/min/1.73 m²).

  • Have a 12-lead Electrocardiogram (ECG) abnormality that, in the opinion of the investigator,

  • increases the risks associated with participating in the study

  • may confound ECG data analysis

  • Have used or intend to use over-the-counter or prescription medication including dietary or herbal medications within 7 days, or 14 days if the medication is a potential enzyme inducer, or 5 half-lives (whichever is longer), prior to dosing.

  • Smoke more than 10 cigarettes per day or the equivalent, including electronic cigarettes, and are unable to abide by investigative site smoking restrictions.

  • Have an average weekly alcohol intake that exceeds 14 units per week (males 65 years of age or younger) and 7 units per week (females and males greater than 65 years of age, if applicable)

  • Show evidence of

  • Human immunodeficiency virus (HIV) infection and/or positive human HIV antigen and/or antibodies

  • hepatitis C and/or positive hepatitis C antibody

  • hepatitis B and/or positive hepatitis B surface antigen.

  • Have liver disease.

  • Any clinical condition or procedure (for example, gastrointestinal obstruction, gastric bypass, or cholecystectomy) that may affect the absorption, distribution, or excretion of the study drug and confound pharmacokinetics (PK) assessment.

  • Part C Only:

    • Have history of neuropathy of any cause.
    • Have impaired hearing or a history of hearing problems.
    • Have any medical conditions, medical history, or are taking any medications that are contraindicated in the itraconazole prescribing information, such as prior history of hypersensitivity to itraconazole or other azoles.
    • Participants with any known history of thyroid disease
  • Participants in the Combined Oral Contraceptive Arm of Part C only:

    • Are current smokers or have used nicotine, including tobacco or nicotine replacement products within 14 days prior to the first dose of combined oral contraceptive (COC), or plan to use nicotine, including tobacco or nicotine replacement products during the study.
    • Are at high risk for arterial or venous thrombotic diseases, autoimmune disease with lupus anticoagulants or anti-phospholipid syndrome, major surgery within the past 3 months, anticipated prolonged immobility.
    • Have abnormalities indicative of increased risk of VTE on the thrombophilia panel at screening.
    • Have undiagnosed abnormal uterine bleeding.
    • Have any history of breast, uterine or ovarian cancer.
    • Use of Vitamin C (greater than or equal to (≥) 500 mg/day) or acetaminophen within 14 days before dosing.
    • Have contraindications for the use of levonorgestrel/ethinyl estradiol.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Grundläggande vetenskap
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: LY4515100 of Part A (SAD)

Single-ascending doses of LY4515100 will be given orally

given orally

Experimentell: LY4515100 of Part B (MAD)

Multiple-ascending doses of LY4515100 will be given orally

given orally

Experimentell: LY4515100 and Itraconazole of Part C

LY4515100 and Itraconazole will be given orally

given orally

given orally

Experimentell: LY4515100 and Metformin of Part C

LY4515100 and Metformin will be given orally

given orally

given orally

Experimentell: LY4515100 and Transporter Substrates or Renal Marker of Part C

LY4515100 and Transporter Substrates or Renal Marker will be given either orally or intravenously (IV)

given orally

given orally

given orally

given IV

given orally

Experimentell: LY4515100 and Midazolam of Part C

LY4515100 will be given orally. Midazolam will be given orally and IV.

given orally

given orally

given IV

Experimentell: LY4515100 and Combined Oral Contraceptive of Part C

LY4515100, Levonorgestrel, and Ethinyl Estradiol will be given orally

given orally

given orally

given orally

Placebo-jämförare: Placebo Part A

Placebo will be given orally

given orally

Placebo-jämförare: Placebo Part B

Placebo will be given orally

given orally

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of participants with one or more serious adverse event(s) (SAEs) of LY4515100 in Parts A and B
Tidsram: Day 1 up to Day 30

SAEs of LY4515100

Day 1 up to Day 30

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
PK: Geometric Means of Area Under the Concentration-Time Curve From 0 to Infinity [AUC(0-∞)] of LY4515100 in Combination with Itraconazole versus LY4515100 Alone
Tidsram: Day 1 through Day 50
Day 1 through Day 50
PK: Geometric Means of Cmax of LY4515100 in Combination with Itraconazole versus LY4515100 Alone
Tidsram: Day 1 through Day 50
Day 1 through Day 50
PK: Geometric Means of AUC(0-∞) of Substrate in Combination with LY4515100 versus Substrate Alone
Tidsram: Day 1 through Day 36
Day 1 through Day 36
PK: Geometric Means of Cmax of Substrate in Combination with LY4515100 versus Substrate Alone
Tidsram: Day 1 through Day 36
Day 1 through Day 36
Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of LY4515100
Tidsram: Day 1 through Day 11

PK: AUC of LY4515100

Day 1 through Day 11
PK: Maximum Observed Drug Concentration (Cmax) of LY4515100
Tidsram: Day 1 through Day 11

PK: Cmax of LY4515100

Day 1 through Day 11
PK: Time of maximum observed drug concentration (tmax) of LY4515100
Tidsram: Day 1 through Day 11

PK: tmax of LY4515100

Day 1 through Day 11

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

15 januari 2026

Primärt slutförande (Beräknad)

1 mars 2027

Avslutad studie (Beräknad)

1 mars 2027

Studieregistreringsdatum

Först inskickad

6 januari 2026

Först inskickad som uppfyllde QC-kriterierna

6 januari 2026

Första postat (Faktisk)

14 januari 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

17 november 2026

Senast verifierad

1 november 2026

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera